Search | Clinical Trials Finder

Conditions: Asthma
Interventions: FF/UMEC/VI, ELLIPTA, FF/VI; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 21 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 27,190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate/Vilanterol, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more

Conditions: Asthma
Interventions: tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 36
States / cities: Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 30 more

Conditions: Asthma
Interventions: Tezepelumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more

Conditions: Copd
Interventions: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more

Conditions: Asthma
Interventions: dupilumab, Matching Placebo, ICS/LABA; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 51
States / cities: Bakersfield, California • La Jolla, California • Lancaster, California + 47 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 11
States / cities: Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,031 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 47
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 42 more

Conditions: Asthma, COPD
Interventions: MGR001, Advair® Diskus®, Seretide™ Accuhaler™; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
Interventions: PARTICS using a single ICS add on, MART; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Interventions: HDM SLIT-tablet, Placebo; Biological · Other
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Miami, Florida • Columbus, Georgia • Ypsilanti, Michigan + 4 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more

Conditions: Asthma
Interventions: Mepolizumab, Placebo, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 94
States / cities: Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Lakewood, California + 46 more

Conditions: Asthma, Nonadherence, Medication
Interventions: Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Moderate to Severe Asthma
Interventions: povorcitinib, placebo, ICS-LABA; Drug · Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Bakersfield, California • Upland, California + 18 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 90
States / cities: Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more

Conditions: COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions: Roflumilast, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 2,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 217
States / cities: Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more

Search by objective public record fields.

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

Mite Asthma Pediatric Immunotherapy Trial

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

VENTURI (VENTilation Using Respiratory Imaging)

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)